TXL treatment may reduce the incidence of recurrent plaque rupture and healing, thus retarding the progression of carotid plaque, which is supported by the TXL treatment lowering the incidence of unstable angina pectoris in our patients. Here, TXNL1 is linked to intermediate coronary syndrome.